X4 Pharmaceuticals, Inc.

Please stand by, your program is about to begin. Greetings and welcome to this X4 Pharmaceuticals call and webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Dan Ferry, from LifeSci Advisors. Please begin.

Thank you, Operator, and good morning, everyone. Thank you for joining us today for this special earnings call, during which X4 will focus on providing a business update and, importantly, data and results from its now-completed Phase 2 study of Mavericks 4 and chronic neutropenia. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development and commercialization plans. as well as research activities and financial projections. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Discretion of these risks can be found in X4's most recent filings with the SEC, including this year's Form 10-K, which was filed on March 21, 2024, and in the company's Form 10-Q for the third quarter, which is expected to be filed shortly. Presenting on today's call will be Dr. Paula Regan, X-Force President and CEO, and the company's Chief Medical Officer, Dr. Christoph Arvid Engels. I'll now turn it over to Paula Regan to run through today's agenda.

Paula? Thank you, Dan, and thank you all for joining us.